Ranibizumab is used in the treatment of wet form of age-related macular degeneration, diabetic macular edema and macular oedema due to retinal vein occlusion.

Ranibizumab is a monoclonal antibody, used to treat several eye diseases causing vision impairment. It works by stopping abnormal blood vessel growth and leakage in the eye(s) that occur due to excess human vascular endothelial growth factor A (VEGF-A), thereby preventing from vision loss.

Conjunctival hemorrhage, Eye pain, Eye inflammation, Eye floaters, Increased intraocular pressure

• Patients should not drive or use machines immediately after receiving ranibizumab intravitreal injection which may influence the driving ability or ability to operate machines.
• Consult your ophthalmologist immediately if the eye becomes red, sensitive to light, painful or develops a change in vision.
• Before taking ranibizumab, inform you doctor if you are pregnant, planning a pregnancy or breast-feeding.

Ques. Q. Is Ranibizumab FDA approved?
Yes, Ranibizumab is approved by the FDA

Ques. Q. What is Ranibizumab injection and how does it work?
Ranibizumab injection belongs to a class of medications called vascular endothelial growth factor (VEGF) antagonists. Ranibizumab is used for the treatment of conditions that affect vision such as exudative (wet) neovascular age-related macular degeneration (AMD), macular edema (swelling) following retinal vein occlusion and macular edema (swelling) due to diabetes. Ranibizumab binds extracellular VEGF thereby stopping abnormal blood vessel growth and leakage in the eye(s) which may lead to vision loss in people with wet AMD.